Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regadenoson versus central intravenous adenosine for FFR hyperemia assessment
NL-OMON37223Phase 4Active, not recruiting
- Sponsor
- Catharina Ziekenhuis
- Start
- Jan 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of regadenoson and adenosine in coronary arteriosclerosis (3 arms), sponsored by Catharina Ziekenhuis. Primary endpoints: Degree of coronary hyperemia and Duration of hyperemic plateau phase. Started Jan 2013; status: active, not recruiting.
02
Drugs
regadenosonadenosine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON37223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37223.